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ABSTRACT
Introduction: Patients with fibromyalgia
syndrome (FMS) generally present with
chronic widespread pain, accompanied by a
range of additional and non-specific symptoms,
such as fatigue, disturbed sleep, and cognitive
dysfunction, which tend to increase with
overall severity. Previous studies have shown
moderate cognitive impairment in patients
with FMS, but there are few valid data
explicitly assessing the relevance of these
findings to everyday functions, such as driving
ability. Therefore, we studied patients with FMS
to assess the impact of FMS on tests that predict
driving ability.
Methods: Female patients with FMS were
prospectively compared to a historical control
group of healthy volunteers. The test battery
comprised assessments of visual orientation,
concentration, attention, vigilance, motor
coordination, performance under stress, and
reaction time.
Results: A total of 43 patients were matched to
129 controls. The results indicated that the
patients’ psychomotor and cognitive
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performances were significantly non-inferior
when compared to healthy controls (with
0.05% alcohol), with the exception of motor
coordination. Patients and healthy controls
showed an age-related decline in test
performance. Correlations were smaller in
patients and reversed for vigilance which was
linked to a greater FMS symptom load in
younger patients.
Conclusion: The results of the present study
demonstrate that, in general, the driving ability
of patients with FMS was not inferior to that of
healthy volunteers based on a standardized
computer-based test battery. However,
variables, such as younger age, depression,
anxiety, fatigue, pain, and poor motor
coordination, likely contribute to the
subjective perception of cognitive dysfunction
in FMS.
Keywords: Chronic pain; Driving ability;
Fibromyalgia; Neurocognitive function; Vienna
test system
INTRODUCTION
Patients with fibromyalgia syndrome (FMS), a
chronic widespread pain syndrome of unknown
pathophysiology, generally show diffuse and
generalized musculoskeletal pain accompanied
by reduced pain thresholds (i.e., the presence of
tender points) which may represent evidence of
central sensitization. Other typical clinical
features include sleep disturbance, fatigue, and
morning stiffness [1]. Although the traditional
classification criteria (American College of
Rheumatology 2010) remain controversial [2],
in agreement with other countries, 3–4% of the
German population is affected with FMS [3].
In addition to pain and fatigue, FMS patients
often present with substantial yet subjective
physical and cognitive impairments [4–7].
Several studies have replicated these subjective
reports using more objective and standard tests
and have identified subtle cognitive
impairments in patients with FMS [7–10]. No
study data have explicitly assessed the clinical
relevance of these findings, although significant
impairments in the functions of daily living
have been convincingly demonstrated for
patients with FMS [11]. In addition, these
patients are often treated in clinical practice
with centrally acting analgesics and co-
analgesics [12, 13], despite overall mixed
evidence for their long-term effectiveness [14].
Thus, the cognitive functions of these patients
may be impaired by both the syndrome and by
its pharmacological treatment.
Safely driving a motor vehicle requires a
complex interaction of operational, physical,
cognitive, perceptual, and psychological skills.
Because driving ability depends on complex
psychomotor and cognitive skills, national and
international recommendations indicate that
tests should examine concentration, attention,
reaction time, and an individual’s performance
and orientation while under stress. These skills
may be assessed by computerized
neuropsychological test batteries, such as the
Vienna test system [15], by driving simulators
[16], or by road tests [17].
Because driving ability is considered an
important aspect of self-determination and
social participation, previous studies in the
pain field using this methodology have
focused on the effect of opioids on the
complex psychomotor and cognitive functions
of non-cancer patients under long-term opioid
therapy and in drug addicts in opioid
substitution programs [15, 18–23]. Only a few
studies have examined the impact of chronic
pain on complex psychomotor and cognitive
tasks. According to a systematic review of the
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quality and generalizability of studies on the
effects of opioids on driving and cognitive/
psychomotor performance [24], high levels of
pain may also affect aspects of these complex
tasks. Moreover, it is important to note that
cognitive impairment may occur in patients
only when pain intensity levels exceed a certain
threshold, which has been located between 64
and 71 of 100 [25]. However, even low-level
pain may interfere with complex tasks, resulting
in less accuracy and reduced performance speed
[26]. Furthermore, any pain-related disruptions
of attention seem to be worsened through such
factors such as pain catastrophizing [27].
Driving ability can be compromised if one or
more of the aspects involved in cognitive and
psychomotor functions, such as attention,
reaction time, visual orientation, perception,
vigilance, and motor coordination, are impaired
[15, 19, 20, 22]. To assess all of these factors, a
battery of tests and statistical analyses complying
with international recommendations, as well as
with German legislation, were applied [28–33].
We included only patients with FMS currently off
medication to assess the impact of FMS itself on
tests that predict driving ability.
METHODS
This was a prospective comparison of patients
with FMS and a historical group of healthy
volunteers. Subjects and controls were matched
for age and sex, with three controls selected for
every patient with FMS. The controls were not
matched for educational level and social status,
as the corresponding data for the control group
(CG) were not available.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study. The study protocol and the
consent form were approved by the ethics
committee of the University of Cologne
(Ethics Committee number 04-005).
Patients
Female outpatients older than 18 years suffering
from FMS were enrolled. All patients included were
required to fulfill the ACR 1990 criteria by Wolfe
[1]. Patients were also questioned about the onset
of chronic pain and when a diagnosis of FMS was
made first. In addition, the diagnosis was
confirmed by an experienced physician (FP) with
regard to FMS when patients presented to our pain
clinic. All patients had to stop pharmacological
pain treatment with centrally acting agents after
screening and at least 1 week prior to the actual
computer test. Participants also required a valid
driver’s license and the ability to speak, read and
write German fluently. Patients were excluded
from the study if they were receiving strong opioid
analgesics, benzodiazepines, barbiturates,
pharmacotherapy for a diagnosis of depression,
or regular antihistamines. Patients with physical
disabilities, severe psychiatric or neurological
diseases or visual disorders that would prevent
them from performing the tests were also
excluded. All patients gave written, informed
consent for their participation prior to any study
procedures. The study protocol and the consent
form were approved by the ethics committee of
the University of Cologne (Ethics Committee
number 04-005).
Control Group
Controls were randomly selected from a pool of
healthy volunteers who had been tested
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between March 1996 and March 1998 (between
2 and 5 p.m.) at the Institute for Traffic Safety of
the German Technical Monitoring Association
in Cologne, Germany. This pool was part of a
larger sample composed of healthy volunteers,
with five men and five women for each year of
age from 18 to 80 years. The control sample was
described as representative of the normal
German population with regard to activity,
autonomy, and driving experience [30, 34].
Course of the Study
Initially, personal details (age, gender, etc.) and
medical histories were recorded, including full
details of their pain disease and the treatments
they were receiving. Participants were also asked
about their driving experience. Testing was
performed between 12 and 3 p.m. at least
1 week after screening. Prior to testing, a urine
sample was taken to screen for the use of drugs
possibly not reported by the patients at the time
of screening and to verify the discontinuation
of medical treatment (urine was screened for
opioids, antidepressants and anticonvulsants as
well as benzodiazepines and hypnotics). Pain
intensity was rated immediately before testing
using a visual analog scale (VAS) ranging from
0 mm (no pain) to 100 mm (worst pain that can
be imagined).
Questionnaires
For the assessment of relevant patient
characteristics, we applied various
questionnaires. The long form of Beck
Depression Inventory (BDI) was used for the
detection and assessment of depression, and the
overall summary score was used for analysis [35].
The Short Form (SF)-36 contains 36 items
and measures eight domains of health: physical
functioning, role limitations due to physical
health, bodily pain, general health perceptions,
vitality, social functioning, role limitations due
to emotional problems, and mental health. The
SF-36 yields a score for each of these domains, as
well as summary scores for both physical and
mental health and a single health utility index
[36].
The short form of the McGill Pain
Questionnaire (SF-MPQ) is one of the most
widely used tests for the measurement of pain.
It provides valuable information on the sensory,
affective and evaluative dimensions of the pain
experience and is capable of discriminating
between different pain problems. The main
component of the SF-MPQ consists of 15
descriptors (11 sensory; 4 affective), which are
rated on an intensity scale as 0 = none,
1 = mild, 2 = moderate, or 3 = severe. Three
pain scores are derived from the sum of the
intensity rank values of the words chosen for
sensory, affective, and total descriptors [37].
The Brief Pain Inventory (BPI) is a
comprehensive instrument for pain assessment
and has been validated in the German language
[38]. The BPI measures both the intensity of
pain (average, worst, and recurrent pain) and
the interference of pain in the patient’s life
(reactive dimension) [39].
The Brief Fatigue Inventory (BFI) was
constructed to assess the severity and
impairment from fatigue and has been
validated in the German language [40]. The
BFI measures the intensity of fatigue (average,
worst, and current fatigue) and is interference
with function.
The State-Trait Anxiety Inventory (STAI) is
composed of separate self-reported scales to
measure state anxiety (A-State) and trait
anxiety (A-Trait). The A-Trait scale
discriminates between subjects based on their
disposition to respond to psychological stress
with different levels of current or A-State
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intensity. Trait anxiety refers to relatively stable
individual differences in anxiety proneness; in
other words, this concept refers to differences
among subjects in their tendencies to respond
to situations perceived as threatening with
elevations in A-State intensity [41].
Test Battery
The test battery followed the German national
recommendations for tests used to determine
driving ability [42], which require the
assessment of (1) performance under pressure,
(2) orientation, (3) concentration, (4) attention
and (5) reaction time. Using our tests (described
subsequently), each of these five domains was
covered. Test batteries similar to the ones used
in this study are commonly used for traffic
delinquents in Germany; in this cases,
permission to drive is usually denied if
subjects fail on one or more of these tests, i.e.,
if the test result is below the 16th percentile of
the age-independent reference range (based on
data from a group of young healthy volunteers)
[33]. In addition, previously validated tests for
motor coordination and vigilance were also
used in this study.
All tests were performed under
standardized conditions with standardized
instructions and in the same sequence using
computerized test system (Vienna test
system). There was no interaction between
the tester and the tested subject, except in
instances of failure understanding the test
procedures, in which case the test
instructions could be repeated and
explained. Raw data, as well as combined
scores, were measured. The entire test battery
normally takes approximately 75 min to
perform, with the vigilance test at the end
taking 25 min.
Test for Reaction Time Under Pressure
(Determination Test; DT)
Subjects were given a series of different audio–
visual signals. Color symbols were presented on
the screen and acoustic signals had to be
answered using the corresponding buttons on
the panel, while the symbols on the right or left
sides of the screen also had to be answered using
the corresponding pedals. The frequency of the
stimuli was automatically adapted to the
subject’s response. This test took 240 s, and
the mean time to a correct response [i.e., mean
reaction time (MRT)] was used as the score [43].
Attention Test (Cognitrone Test; COG)
Four pictures (numbers, letters, figures, etc.)
were presented in a row, with another picture
presented below. Subjects had to decide
whether the lower picture matched any of the
four pictures above. A new set of pictures was
presented either after a response or
automatically after 1.8 s. Up to 200 sets of
pictures were used in this test. The number of
correct and incorrect responses, and the MRT
were recorded for a given subject. The overall
score was calculated as the sum of the MRT and
the square root of the product of the MRT and
the wrong answers [44].
Test for Motor Coordination (2-Hand)
The subjects had to keep a signal on a track by
simultaneously turning two steering wheels:
one controlling horizontal movements and the
other controlling vertical movements. The track
consisted of three different sections (circle, V-
shape, and L-shape) and had to be negotiated 19
times. The mean time taken to negotiate the
track (T, in seconds) and the mean percentage
of the total time during which the signal was off
the track (Off %) were recorded. The score was
calculated as T Off %ð Þ=100þ 0:1 T [45].
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Vigilance Test (VIG)
Subjects were presented with a circle consisting
of separate small white spots on a dark monitor.
A bright spot moved stepwise around this circle,
similar to the hand of a watch. At long but
irregular intervals, the spot sometimes missed
one of the positions (i.e., jumped over one of
the marker spots). When this occurred, the
subjects had to press a button as quickly as
possible. The number of mistakes (incorrect
responses or undetected jumps) and the MRT
were recorded. The score was calculated as the
sum of the MRT and the square root of the
product of the MRT and the sum of the missed
and wrong answers [46].
Statistical Methods
Non-Inferiority
The study was designed as a non-inferiority
trial; i.e., the objective was to demonstrate that
patients with FMS do not perform significantly
worse in the tests than controls. This means,
that their performance was not inferior when
compared to the control group.
In such non-inferiority trials, a clinically
significant difference (delta, d) from the
standard outcome or performance must be
defined. Typically, cognitive performance
under the influence of defined levels of
alcohol has been used as a standard to assess
the degree of impairment induced by several
drugs [47]. A blood alcohol level of C0.05% has
been shown to cause a marked impairment in
driving ability and is the threshold for being
unfit to drive under German law [48–50]. In a
previous study, the effect of different
antidepressants on cognitive and psychomotor
functions was compared using a computerized
test battery similar to our study. During this
study, patients received alcohol orally with a
targeted blood concentration of 0.05%. The
strongest impairment was observed in the
testing of vigilance [49]; from the data in this
previous study, an effect size of d = 0.57 for the
alcohol-related impairment of vigilance was
calculated. Using this effect size, the raw
values of the control group in our study were
transformed to obtain virtual values that would
be equivalent to test performance under the
influence of a 0.05% blood alcohol level.
Using this assumption, non-inferiority in the
test battery results of the fibromyalgia patients
compared to controls could be interpreted as a
performance significantly better than that of
the CG with a blood alcohol concentration of
0.05%, which likely reflects sufficient fitness to
drive. In accordance with prior studies from our
group with patients on acute and chronic
opioid therapy [15, 19, 20, 22, 51], we used
1:3 randomizations to increase the power of the
study. With 43 patients and 129 controls, the
power of this study was calculated to be close to
1 (one-sided t test, a = 0.05).
Each of the five tests used involved the
recording of several parameters. To reduce the
problem of multiple testing, one ‘relevant score’
for each test was defined prior to the analysis of
the study data.
Passed Tests
Another method for evaluating driving ability
using the various cognitive tests previously
described is to assume unimpaired driving
ability only if all test results are above the
16th percentile of the age-independent
reference range [33]. Accordingly, for both
subjects with FMS and healthy controls, the
passing of the 16th percentile was recorded
using the original raw data and not the
transformed data reflecting the influence of
alcohol.
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Secondary Analysis
In the secondary analysis, the effects of age on
the test results of the two groups were explored,
as well as the rates of correct versus incorrect
responses.
Statistical Testing
The Mann–Whitney U test was used because a
normal distribution of the data could not be
ascertained for all parameters. Because the
direction of the expected change in a
non-inferiority trial is defined, a one-sided
P value \0.05 was regarded as significant. Data
on passing rates or the 16th percentile were
compared using the v2 square test. Significance
tests for parameters other than the primary
endpoints were exploratory in nature and were
performed two-sided without adjustment for
multiple comparisons. Correlational analyses
were performed using Spearman’s rho
correlation coefficient for non-parametric
analysis. Unless stated otherwise, the results are
presented as arithmetic means ± standard
deviation (SD).
RESULTS
A total of 43 female outpatients were enrolled in
the study and matched with 129 controls in a
3:1 fashion. As an expected result of matching,
the study and control populations included
only women with similar age (Table 1). In
patients, the mean duration of pain was
248 ± 164 months (range 36–720). The mean
duration of time after the initial diagnosis of
FMS was 71 ± 49 months (range 1–192). The
mean current pain intensity was rated as
54 ± 21 mm with the VAS (0 mm: no pain;
100 mm: worst pain that can be imagined).
Urine screening detected no unreported use of
drugs and compliance with the withdrawal
procedures. The data from all 43 patients were
analyzed in accordance with the study protocol
and the results of the tests are displayed in
Table 2.
DT
Significant non-inferiority of the FMS group was
detected with regards to the number of ‘‘correct
answers’’, the number of ‘‘wrong answers’’ and
the ‘‘MRT’’ (=summary score) compared to the
CG ? d (P\0.05). The number of ‘‘omitted
answers’’ was higher in the CG ? d than the
FMS group, but this difference was not
statistically significant (Table 2).
COG
Significant non-inferiority of the FMS group was
detected with regards to the number of ‘‘wrong
answers’’ and the overall score compared to the
CG ? d (P\0.01). Although the number of
‘‘correct answers’’ for the FMS group was
higher compared to the CG ? d, this difference
did not reach statistical significance. Therefore,
non-inferiority could not be demonstrated for
this item. The MRT for performing this test was
higher and therefore slower in the FMS group
compared to the CG ? d (P\0.01 with a two-
sided Mann–Whitney U test, Table 2). The low
number of wrong answers likely explains the
non-inferiority in the overall score, as it
compensated for the slowest reaction times.
2-Hand
The average time needed to complete the test
was significantly non-inferior in the FMS group
(P\0.01). However, the analysis of the
percentage of ‘‘time off track’’ failed to show a
significant non-inferiority of the FMS group
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compared to the CG ? d. In fact, FMS patients
even tended to have a longer time off track (in
%) when compared to the CG ? d. Accordingly,
the calculated test score also failed to
demonstrate statistically significant non-
inferiority when compared to the CG ? d
(Table 2).
VIG
The difference in the number of ‘‘correct
answers’’, ‘‘wrong answers’’, ‘‘omitted answers’’,
the MRT and the scores for the FMS group
proved to be significantly non-inferior
compared to the CG ? d (P\0.01; Table 2).
Passed Tests
The percentages of patients who passed the
single tests, that is, those whose relevant test
scores were above the 16th percentile
compared to an age-independent reference
group (RG), are displayed in Fig. 1. The
subjects from the RG passed an average of
3.2 (SD = 1.4) of the four tests, which was
similar to the patients from the FMS group,
with 3.2 (SD = 1.3) passed tests. The
percentage of subjects passing all four tests
was 60% for the RG and 51% for the FMS
group (P = 0.08). In the DT and 2-Hand, fewer
patients from the FMS group reached the 16th
Table 1 Demographic data
Characteristic FMS group (n 5 43) Control group (n 5 129)
Gender (female), n (%) 43 (100) 138 (100)
Age (years), mean ± SD (range) 55 ± 9 (38–75) 55 ± 10 (38–75)
Duration of chronic pain (months), mean ± SD (range) 248 ± 164 (36–720)
Duration of FMS (months), mean ± SD (range) 71 ± 49 (1–192)
Current pain intensity (BPI), mean ± SD (range) 54 ± 21 (1–89)
Current driving (km/year), mean (range) 8,349 (200–30,000)
Driving experience (years), mean ± SD (range) 32 ± 9 (4–45)
BDI score, mean ± SD (range) 16 ± 9 (3–45)
BPI—average pain score, mean ± SD (range) 95 ± 47 (16–168)
BPI—interference score, mean ± SD (range) 34 ± 13 (4–61)
BFI—average score, mean ± SD (range) 16 ± 6 (3–27)
BFI—interference score, mean ± SD (range) 27 ± 14 (1–52)
SF-36 physical summary score, mean ± SD (range) 28 ± 7 (16–45)
SF-36 mental summary score, mean ± SD (range) 40 ± 13 (17–69)
STAI A-state score, mean ± SD (range) 44 ± 10 (24–77)
STAI A-trait score, mean ± SD (range) 48 ± 12 (29–76)
A-state state anxiety, A-trait trait anxiety, BFI Brief Fatigue Inventory, BPI Brief Pain Inventory, FMS fibromyalgia
syndrome, SF-36 short form 36, STAI State-Trait Anxiety Inventory
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percentile compared to the RG. The
percentage of patients passing the test was
higher for the FMS group in terms of the COG
but the same for the VIG compared to the RG.
None of these differences were statistically
significant.
Secondary Analysis
To assess the potentially different effects of age
on the results of the cognitive testing, age was
correlated with all four primary scores in
patients with FMS and in the CG ? d
Table 2 Psychomotor and cognitive performance measures including the calculated score of the different tests
Parameter FMS group Control group
Raw values Raw values 1 d
DT (n) 43 129 129
Correct answers (n) 210.8 – 36.987# 214.2 ± 37.3 192.9 ± 36.5
Wrong answers (n) 6.7 – 5.5## 9.4 ± 9.0 14.5 ± 9.0
Omitted answers (n) 11.3 ± 6.2 9.4 ± 5.2 12.3 ± 5.2
Score = MRT (s) score 0.9 – 0.2# 0.9 ± 0.1 1.0 ± 0.1
COG (n) 43 129 129
Correct answers (n) 48.3 ± 10.5 52.4 ± 10.9 46.2 ± 10.9
Wrong answers (n) 18.6 – 7.8## 31.6 ± 16.7 41.1 ± 16.7
MRT (s) 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
Score 5.8 – 1.0## 6.8 ± 1.3 7.6 ± 1.3
2-Hand (n) 43 129 129
Mean time (s) 46.6 – 24.0## 47.0 ± 19.8 58.3 ± 19.8
Time off track (%) 3.8 ± 3.3 2.0 ± 1.6 2.9 ± 1.6
Score 8.4 ± 4.5 6.7 ± 3.2 8.5 ± 3.2
VIG (n) 43 129 129
Correct answers (n) 95.4 – 8.8## 97.3 ± 4.2 94.9 ± 4.2
Wrong answers (n) 2.2 – 3.0## 4.9 ± 6.8 8.8 ± 6.8
Omitted answers (n) 4.6 – 8.8## 2.7 ± 4.2 5.1 ± 4.2
MRT (s) 0.5 – 0.1## 0.5 ± 0.1 0.6 ± 0.1
Score 2.0 – 1.5## 2.2 ± 1.2 2.8 ± 1.2
2-Hand test for motor coordination, COG Cognitrone test, DT determination test, FMS fibromyalgia syndrome, MRT
mean reaction time, VIG vigilance test
The results are presented as arithmetic means ± the standard deviation. The results of the control group are presented as raw
values, as are the calculated results of the effect of impairment due to an alcohol level of 0.05% [raw values transformed by d
(calculated effect size for alcohol-related impairment of vigilance) and the variance of the item in the whole sample]
Bold: Significant non-inferiority of the FMS group compared to the control group ? d (#P\0.05, ##P\0.01)
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(Table 3). The correlational relationships were
generally positive for the two groups, with
coefficients being smaller in the FMS group.
The VIG score showed a negative relationship
in patients with FMS compared to a weak, but
positive relationship in the CG ? d. This
indicates decreases in test performance
(greater scores) with increasing age for most
parameters, independent of the group status.
However, the relatively greater overall disease
burden in younger FMS patients compared to
both older patients and age-matched healthy
controls may explain the discrepant VIG
finding and the smaller correlation
coefficients. This notion is supported by the
significantly negative correlations between age
and BDI score (q = -0.44, P\0.003), trait
anxiety (STAI-T, q = -0.43, P\0.004), and
fatigue scores (BFI, q = -0.42, P\0.004) but
not pain scores (BPI, q = -0.25, P = 0.15) in
patients with FMS.
The ratio of wrong to correct answers is
shown in Table 4. Patients with FMS showed
overall fewer false responses in the VIG, COG,
and DT tests, even when corrected for the
number of correct responses. This result was in
contrast to the increase observed for the time
and percentage of ‘‘time off track’’ observed in
FMS patients in the 2-Hand test.
DISCUSSION
The present study examined the psychomotor
and cognitive performance of FMS patients to
predict their driving ability. Using tests to assess
impairment of driving ability in clinical practice
for all sorts of conditions we failed to show a



















Fig. 1 Percentage of passed tests. Percentage of all passed
tests (test score above the 16th percentile). 2-Hand test for
motor coordination, CG age-independent reference group,
COG Cognitrone test, DT determination test, FMS
fibromyalgia syndrome, MRT mean reaction time, VIG
vigilance test
Table 3 Correlation of age with the four main scores for
the two groups (Spearman Rho, level of significance)
Score FMS group Control group
DT score 0.44, P\0.003 0.75, P\0.0001
COG score 0.30, P\0.05 0.42, P\0.0001
2-Hand score 0.43, P\0.004 0.55, P\0.0001
VIG (n) -0.38, P\0.013 0.20, P\0.025
2-Hand test for motor coordination, COG Cognitrone
test, DT determination test, FMS fibromyalgia syndrome,
VIG vigilance test
Table 4 Percentage of wrong answers in % of correct
answers
Parameter FMS group Control group
Raw values Raw values 1 d
DT (n) 43 129 129
Wrong/correct (%) 6.7 – 5.5# 9.4 ± 9.0 14.5 ± 9.0
COG (n) 43 129 129
Wrong/correct (%) 18.6 – 7.8## 31.6 ± 16.7 41.1 ± 16.7
VIG (n) 43 129 129
Wrong/correct (%) 2.2 – 3.0## 4.9 ± 6.8 8.8 ± 6.8
d calculated effect size for alcohol-related impairment of vigilance, COG
Cognitrone test, DT determination test, FMS fibromyalgia syndrome,
VIG vigilance test
Bold: Significant non-inferiority of the FMS group compared to the
control group ? d (# P \ 0.05, ## P \ 0.01)
94 Pain Ther (2014) 3:85–101
patients with FMS. The relevant summary scores
of the DT (reaction time), COG (attention), and
the vigilance score were significantly non-
inferior compared to the control group
(CG ? d). Only in the 2-Hand test (motor
coordination) could significant non-inferiority
of the score not be reached due to the results for
‘‘time off track’’ in the FMS group. In addition,
patients with FMS and control subjects showed
similar rates of passed tests.
The impairment of cognitive functions in
FMS patients is a core symptom reported by
patients, but the severity and clinical relevance
of these impairments have been questioned
[52]. Several authors reported a significant
impairment in cognitive performance in
patients with FMS, with greatest agreement in
tests of working memory performance [7, 53–
55]; however, other studies did not find
evidence of cognitive impairment in patients
with FMS [56–58] and highlighted the
importance of examining the influence of co-
variables, such as pain severity, fatigue,
depression, and required effort, on cognitive
performance in FMS [10, 58].
Despite the evidence for poor performance
in functions of daily living in FMS [11], the
contribution of cognitive dysfunction has not
been established. This study of driving-related
abilities demonstrates one potential avenue to
address this clinically relevant interaction. In
contrast to many other studies, and following
the recommendations of some authors [47], the
effect of alcohol was used in our study as a ‘‘real-
world’’ endpoint and an important benchmark
for clinical relevance, as its impact on complex
psychomotor performance is well documented
and quantifiable. The blood alcohol
concentration of 0.05% blood alcohol was
chosen as a benchmark according to the
German legislation and previous studies [15,
19, 22, 34]. From this perspective, the current
results indicated that irrespective of the levels of
individual symptomatology and severity,
patients with FMS as a group did not perform
worse than the normal population under the
influence of a 0.05% blood alcohol level. This
finding does not exclude the presence of
cognitive dysfunction in individual patients
with FMS, but rather indicates that these
changes do not result in relevant impairment
of driving ability.
Published studies examining FMS and its
influence on cognition and psychomotor
performance show high variability related to
the various methodological approaches used,
ranging from neuropsychological and
computerized tests to neuroimaging, etc. [8,
53–55, 57, 59]. Computerized test batteries can
be designed to measure different aspects related
to driving ability (e.g., reaction time, vigilance,
psychomotor coordination), and their high
capacity for standardization helps to minimize
observer biases. On the other hand, the most of
the neuropsychological tests, especially when
using single tests, are not sufficient for the
effective prediction of potential outcome
measures like, for example, fatalities while
driving a car [60]. However, as proposed by
Lincoln et al. [61] a combination of cognitive
tests might overcome this limitation. In our
study, a combination of different tests, as
proposed by the German legislation, has been
used to assess fitness of driving. To our
knowledge, there has only been one other
study using a computerized neuropsychological
test battery in patients with FMS, and it did not
demonstrate significant differences between
FMS patients and controls [57].
A small yet interesting finding of this study
relates to the poorer results in the 2-Hand test. A
recent study [62] described impaired dexterity
and fine motor control of the hands in patients
with FMS with likewise an increased time
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demand and poorer hand function. This
dysfunction was not linked to individual
symptom load and was related to altered
central motor control.
Several objective measures of cognitive
function have shown subtle differences
between FMS patients and controls. Most
authors agree that memory deficits in FMS
patients are evident and result in subjective
impairments [4, 7–9, 53–55]. Patients with FMS
have been shown to have poorer cognitive
performance than carefully matched adults of
similar age and to perform more like to people
20 years older [63].
Interestingly, in our study age had an overall
negative effect in both groups but correlation
coefficients tended to be smaller in FMS patients
compared to healthy controls for most
parameters. Vigilance even demonstrated a
different pattern with greater relative
impairment in younger FMS patients and more
pronounced symptoms that may indirectly
affect memory function, which was not tested
in our study. This interpretation of a possible
differential effect of age is supported by findings
that older patients show lower reductions of
health-related quality of life than younger and
middle-aged patients, especially on physical
and social dimensions [64].
The results of previous studies on attention
are not uniform [65]. In our study, the FMS
patients’ performance in attention tests (COG
and VIG) was significantly non-inferior to that
of the CG. The tests used in our study evaluated
attention from different perspectives; the VIG
test is based on the assessment of attention in
the form of sustained vigilance in a low-
stimulus observation situation, whereas the
COG test assesses attention and concentration
through comparisons of figures with regard to
their congruence. Glass et al. [8] tested the
processing speed of patients with FMS during a
task (similar to the COG, e.g., ‘‘are two strings of
letters identical or different?’’), and these
authors found that patients with FMS
performed just as well as the age-matched
controls and were significantly faster than the
older controls. This result was supported by the
study of Dick et al. [53], which compared the
attentional functioning of FMS patients to that
of pain-free controls and of rheumatoid arthritis
and musculoskeletal pain patients. FMS patients
performed similar to other patient groups in
any of the investigated domains of attentional
and cognitive functioning, indicating
comparable patterns of attentional
performance among chronic pain patients
with different rheumatologic disorders.
Observed attentional deficits compared to
controls may thus be related more to the
presence of chronic pain than to any specific
disease-related factor [53].
The speed of processing is fundamental to
nearly all cognitive abilities and is viewed as a
global indicator of neurobiological function [7].
Park et al. [7] found no evidence for a deficit in
the speed of processing in their study and
concluded that cognitive dysfunction
associated with FMS thus cannot be viewed
simply as an accelerated form of cognitive
aging. The only conflicting finding in this
study with regard to speed of processing
concerned the MRT in the COG test, which
was slowest (or worst) in the FMS group.
However, exploratory analysis revealed fewer
mistakes in most of the tests by the patients
with FMS, which may reflect cognitive strategies
that result in a slower MRT for the most
complex tasks (COG), which require most
attention. This may also reflect a ‘‘rising to the
occasion’’ or marshaling of resources to perform
well on relatively short cognitive tests [66].
Pain and many of the common comorbid
symptoms of FMS, such as depression, fatigue,
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and sleep disturbances, can have potentially
negative impacts on cognitive function [63].
Due to the lack of data available for the CG in
our study and general non-inferiority, we were
unable to address this relationship. However,
Suhr [10] found that depression was
significantly related to memory performance
and that self-reported fatigue was related to
psychomotor speed. Miro et al. [59] reported
slower overall reaction time, greater interference
and disturbed vigilance in part related to
depression, anxiety, and sleep quality. Similarly,
Dick et al. [53] found a relationship between
depression, anxiety, and cognitive function. In
contrast, in the study of Luerding et al. [55],
neither BDI scores nor pain scores were
significantly correlated with neuropsychological
performance. Furthermore, Park et al. [7] failed to
detect a correlation between depression and
performance on any of the cognitive measures.
The exploratory results of the current study
indicate a potentially greater negative effect of
these comorbid factors (on vigilance) in younger
patients and provide a potential explanation for
the overall discrepant findings. This highlights
the problem of subject selection and
characterization in studies of cognitive function
in FMS.
In a recent study, Landrø et al. [67] reported
of the subjective and objective
neuropsychological functioning measured by a
questionnaire and a neuropsychological test
battery in a heterogeneous sample of 72
patients from a tertiary multidisciplinary pain
clinic. More than 20% of patients scored below
cut-off in the objective tests. A larger proportion
of patients with generalized and neuropathic
pain performed below this cut-off, whereas
patients with localized pain exhibited
impaired function to a lesser degree. Five out
of seven tests were significantly correlated to
subjective impairment. Unfortunately, in the
present study no specific assessment of
subjective neuropsychological symptoms was
performed. In addition, comparison of the two
populations is difficult, as our FMS patients
were off medication and patient’s in the study
of Landrø et al. [67] had different underlying
pain diagnoses and were in part on an analgesic
treatment. All FMS patients were able to
withdraw medication and were driving
actively, with 75% driving more than
4,000 km/year.
The generalizability of the results of our study
for FMS patients thus is limited for several
reasons. First, patients willing to withdraw from
medication or those who do not require any
medication may represent a subgroup with less
severe disease. Second, the unknown educational
level of the CG may have had an impact on the
test results of our study, as we could not exclude a
relevant group difference (patients vs. control) in
educational level. Third, variability in results does
indicate greater (possibly more relevant)
impairment in selected individuals. Fourth,
standardized test batteries only represent
selected aspects of driving ability. Actual driving
performance in a real-world setting may require
practical driving tasks. Longer testing duration
may have revealed more cognitive dysfunction
due to greater fatigability.
CONCLUSION
Using typical tests to assess impairment of
driving ability in clinical practice for all sorts
of conditions, we failed to show a large and
general problem in sample of unmedicated
patients suffering from FMS still actively
driving. However, the significant variability of
the test results indicates relevant FMS-related
impairments in some individuals. Variables
such as younger age, depression, anxiety,
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fatigue, pain, and poor motor coordination
likely contribute to the subjective perception
of cognitive dysfunction in FMS patients.
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